Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease.
Pharmaceutics
December 2024
School of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming 650500, China.
Polycystic ovary syndrome (PCOS) is the predominant endocrine disorder among women of reproductive age and represents the leading cause of anovulatory infertility, which imposes a considerable health and economic burden. Currently, medications used to treat PCOS can lead to certain adverse reactions, such as affecting fertility and increasing the risk of venous thrombosis. Drug delivery systems utilizing nanomaterials, characterized by prolonged half-life, precision-targeted delivery, enhanced bioavailability, and reduced toxicity, are currently being employed in the management of PCOS.
View Article and Find Full Text PDFPolycystic ovary syndrome.
Nat Rev Dis Primers
April 2024
Department of Obstetrics and Gynecology, Research Unit of Clinical Medicine, Medical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland.
Despite affecting ~11-13% of women globally, polycystic ovary syndrome (PCOS) is a substantially understudied condition. PCOS, possibly extending to men's health, imposes a considerable health and economic burden worldwide. Diagnosis in adults follows the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, requiring two out of three criteria - clinical or biochemical hyperandrogenism, ovulatory dysfunction, and/or specific ovarian morphological characteristics or elevated anti-Müllerian hormone.
View Article and Find Full Text PDFBirth outcomes in mothers with hypertensive disorders and polycystic ovary syndrome: a population-based cohort study.
Hum Reprod Open
December 2023
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Study Question: Is polycystic ovary syndrome (PCOS) associated with higher risks of extreme birth size and/or preterm birth in mothers with different hypertension types?
Summary Answer: PCOS was associated with additional risks of preterm birth in mothers with chronic hypertension and in singleton pregnancies of mothers with pre-eclampsia, and with higher risks of offspring born large for gestational age (LGA) in mothers with gestational hypertension.
What Is Known Already: Women with PCOS are more likely to develop gestational hypertension, pre-eclampsia, and chronic hypertension. Although adverse birth outcomes have been frequently reported in mothers with PCOS, such associations in the setting of a hypertensive disorder remain unknown.
Is the Hippo Pathway Effector Yes-Associated Protein a Potential Key Player of Dairy Cattle Cystic Ovarian Disease Pathogenesis?
Animals (Basel)
September 2023
Centre de Recherche en Reproduction et Fertilité (CRRF), Faculté de Médecine Vétérinaire (FMV), Université de Montréal (UdeM), Saint-Hyacinthe, QC J2S 7C6, Canada.
Article Synopsis
- * The role of the Hippo pathway effector yes-associated protein (YAP) has been linked to similar issues in humans and mice, prompting research into its potential involvement in COD.
- * Recent findings show that YAP levels are significantly higher in cystic ovarian cells compared to non-cystic cells, suggesting that YAP may contribute to the development and persistence of ovarian cysts in dairy cattle.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!